Oncology – Bone and Sarcomas | Links Medicus Content Curation & Alerts in Medicine

Single-arm phase 2 study | Activity of Cabazitaxel in metastatic or inoperable locally advanced dedifferentiated liposarcoma.

22 Aug, 2022 | 11:53h | UTC

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) – JAMA Oncology (free for a limited period)

Invited Commentary: Optimizing Histology-Specific Clinical Trials in Soft-Tissue Sarcoma—Are We There Yet? – JAMA Oncology (free for a limited period)

Single-center phase 2 trial | Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas.

11 Aug, 2022 | 11:52h | UTC

Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Online first: #Durvalumab plus #tremelimumab in advanced or metastatic soft tissue and bone #sarcomas: a single-centre phase 2 trial https://t.co/Zt9vTFzBOK pic.twitter.com/BP7fz9FWRw

— The Lancet Oncology (@TheLancetOncol) August 5, 2022

RCT | Doxorubicin alone vs. doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma.

20 Jul, 2022 | 11:36h | UTC

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

RCT: Efficacy and safety of TRC105 plus pazopanib vs. pazopanib alone for treatment of patients with advanced angiosarcoma.

27 May, 2022 | 11:15h | UTC

Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial – JAMA Oncology

Commentaries:

Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma – The ASCO Post

Carotuximab addition to pazopanib does not improve survival in advanced angiosarcoma patients – Physician’s Weekly

Commentaries on Twitter

A phase III trial in 123 patients with advanced-stage angiosarcoma reveals no significant difference in mPFS with pazopanib plus the anti-endoglin (CD105) mAb carotuximab vs pazopanib alone: https://t.co/TPPFRNCOoC #scmsm #caxtx

— NatureRevClinOncol (@NatRevClinOncol) April 5, 2022

First randomized trial in angiosarcoma demonstrates no signif difference in progression-free survival for combo of novel angiogenesis inhibitor carotuximab + pazopanib vs. pazopanib alone in advanced angiosarcoma. https://t.co/f1Z5EjOdK2 pic.twitter.com/qf3Tez9VU2

— JAMA Oncology (@JAMAOnc) March 31, 2022

RCT: Selinexor in advanced, metastatic dedifferentiated liposarcoma.

12 Apr, 2022 | 08:24h | UTC

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial – Journal of Clinical Oncology

Guidelines for diagnosing incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS).

4 Apr, 2022 | 00:45h | UTC

Society of Skeletal Radiology– white paper. Guidelines for the diagnostic management of incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS) – Skeletal Radiology

Commentary on Twitter (article and images under a http://creativecommons.org/licenses/by-nc/4.0/)

Bone RADS- White Paper from @SkeletalRadiol
Want to know how to handle bone lesions? Take a look – open access:https://t.co/mBUFzgJiCf @cychang1414 @ahlawat_shivani @HillaryGarnerMD @mbucknor @Radsdoc82 @behrangamini @IKhodarahmi @JimWuMSK
Apologies couldn't find all authors pic.twitter.com/hL8r04uK40

— Adam Singer, MD (@AdamSingerMD) April 1, 2022